Homozygous BIM deletions have been described in some B-cell lymphomas, including MCL [33,34], and the epigenetic silencing of BIM has been implicated in glucocorticoid resistance in pediatric acute lymphoblastic leukemia (ALL) [35]. Here, BCL2L11 is linked to B-cell non-Hodgkin lymphoma.